NEW YORK, September 29, 2017 /PRNewswire/ --
If you want a Stock Review on GILD, KITE, NVAX, or SGMO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com navigates the Biotech space, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include medical, agricultural, environmental, and industrial. Equities under evaluation this morning are: Gilead Sciences Inc. (NASDAQ: GILD), Kite Pharma Inc. (NASDAQ: KITE), Novavax Inc. (NASDAQ: NVAX), and Sangamo Therapeutics Inc. (NASDAQ: SGMO). Register now and get full and free access to these DailyStockTracker.com research reports at:
On Thursday, shares in Foster City, California headquartered Gilead Sciences Inc. recorded a trading volume of 17.73 million shares, which was above their three months average volume of 9.20 million shares. The stock ended at $80.91, dropping 3.52% from the last trading session. The Company's shares have gained 6.83% in the last one month, 14.18% over the previous three months, and 12.99% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.19% and 13.63%, respectively. Furthermore, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index (RSI) of 47.55.
On September 15th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $94 per share.
On September 27th, 2017, Gilead Sciences announced that Kevin Young CBE, COO, plans to retire, effective early 2018. Mr. Young will remain with the Company through the first quarter of next year and in an advisory capacity thereafter. He joined the Company in 2004 to lead its worldwide commercial operations. Access our complete research report on GILD for free at:
Santa Monica, California headquartered Kite Pharma Inc.'s stock finished yesterday's session 0.03% higher at $179.73 with a total trading volume of 1.13 million shares. The Company's shares have gained 1.00% in the last one month, 74.82% over the previous three months, and 300.83% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 23.49% and 98.98%, respectively. Furthermore, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 91.23.
On August 29th, 2017, research firm Wedbush upgraded the Company's stock rating from 'Underperform' to 'Neutral', with a target price of $180 per share.
On September 26th, 2017, Kite Pharma (KITE) and Gilead Sciences, Inc. announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the latter's cash tender offer for KITE expired at 11:59 p.m. on September 25th, 2017. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to customary closing conditions. The complimentary research report on KITE can be downloaded at:
At the close of trading on Thursday, shares in Gaithersburg, Maryland headquartered Novavax Inc. saw a slight decline of 0.86%, ending the day at $1.15. The stock recorded a trading volume of 3.12 million shares. The Company's shares have advanced 8.49% in the last one month. The stock is trading 4.35% above its 50-day moving average. Moreover, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 54.22.
On September 19th, 2017, Novavax announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-MTM adjuvant (NanoFluTM) in older adults. The trial is a randomized, observer-blinded, active comparator-controlled trial in approximately 330 healthy older adults. Its primary objective is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFluTM compared to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD). Register for free on DailyStockTracker.com and get access to the latest report on NVAX at:
Richmond, California headquartered Sangamo Therapeutics Inc.'s shares ended the day 4.36% higher at $14.35. A total volume of 1.65 million shares was traded, which was above their three months average volume of 1.54 million shares. The stock has gained 12.11% in the last month, 61.24% over the previous three months, and 370.49% on an YTD basis. The Company's shares are trading 26.79% above their 50-day moving average and 110.31% above their 200-day moving average. Additionally, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have an RSI of 62.90. Download your free research report on SGMO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.